Cargando…

Guillain-Barré syndrome in Denmark: validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period

Purpose: To validate the diagnostic codes for Guillain-Barré syndrome (GBS) in the Danish National Patient Registry (DNPR). Secondly, to examine 30-year trends in the incidence of GBS in Denmark. Patients and methods: We used the DNPR to identify all patients aged 16 and above diagnosed with a prima...

Descripción completa

Detalles Bibliográficos
Autores principales: Levison, Lotte Sahin, Thomsen, Reimar Wernich, Christensen, Diana Hedevang, Mellemkjær, Thomas, Sindrup, Søren Hein, Andersen, Henning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497480/
https://www.ncbi.nlm.nih.gov/pubmed/31114387
http://dx.doi.org/10.2147/CLEP.S199839
_version_ 1783415477314256896
author Levison, Lotte Sahin
Thomsen, Reimar Wernich
Christensen, Diana Hedevang
Mellemkjær, Thomas
Sindrup, Søren Hein
Andersen, Henning
author_facet Levison, Lotte Sahin
Thomsen, Reimar Wernich
Christensen, Diana Hedevang
Mellemkjær, Thomas
Sindrup, Søren Hein
Andersen, Henning
author_sort Levison, Lotte Sahin
collection PubMed
description Purpose: To validate the diagnostic codes for Guillain-Barré syndrome (GBS) in the Danish National Patient Registry (DNPR). Secondly, to examine 30-year trends in the incidence of GBS in Denmark. Patients and methods: We used the DNPR to identify all patients aged 16 and above diagnosed with a primary GBS diagnosis at any Danish department of neurology between 1987 and 2016. Medical files were reviewed according to the clinical criteria of the National Institute of Neurological Disorders and Stroke Committee and classified according to the Brighton criteria. The incidence rate (IR) was calculated based on data from 1987 to 2016 and stratified by season, gender, and age. Results: Over 30 years, we identified 2,319 patients aged 16 and above in the DNPR. From a validation cohort of 573 patients, we were able to retrieve 425 (74.2%) medical files; 356 GBS diagnoses were confirmed. The overall positive predictive value was 83.8% (95% confidence interval (CI): 80.0–87.0). In 99% of the confirmed patients, the Brighton criteria level 1–3 for GBS were met. The IR was fairly stable over 30 years at 1.77 per 100,000 person years (95% CI: 1.70–1.84). The incidence was higher in the winter season (IR ratio compared with summer: 1.18 (95% CI: 1.09–1.29)), and was strongly associated with male gender (IR ratio vs females: 1.44 (95% CI: 1.33–1.57)). IRs rose with age at diagnosis, particularly after the age of 50 in both men and women and a minor peak was observed for total IR in young adults. Conclusion: Primary diagnostic codes for GBS at Danish departments of neurology have high validity. The DNPR is a well-suited data source for epidemiological research on GBS. The Danish nationwide 30-year GBS IR is stable over time and similar to GBS IRs reported in other European and North American populations.
format Online
Article
Text
id pubmed-6497480
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-64974802019-05-21 Guillain-Barré syndrome in Denmark: validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period Levison, Lotte Sahin Thomsen, Reimar Wernich Christensen, Diana Hedevang Mellemkjær, Thomas Sindrup, Søren Hein Andersen, Henning Clin Epidemiol Original Research Purpose: To validate the diagnostic codes for Guillain-Barré syndrome (GBS) in the Danish National Patient Registry (DNPR). Secondly, to examine 30-year trends in the incidence of GBS in Denmark. Patients and methods: We used the DNPR to identify all patients aged 16 and above diagnosed with a primary GBS diagnosis at any Danish department of neurology between 1987 and 2016. Medical files were reviewed according to the clinical criteria of the National Institute of Neurological Disorders and Stroke Committee and classified according to the Brighton criteria. The incidence rate (IR) was calculated based on data from 1987 to 2016 and stratified by season, gender, and age. Results: Over 30 years, we identified 2,319 patients aged 16 and above in the DNPR. From a validation cohort of 573 patients, we were able to retrieve 425 (74.2%) medical files; 356 GBS diagnoses were confirmed. The overall positive predictive value was 83.8% (95% confidence interval (CI): 80.0–87.0). In 99% of the confirmed patients, the Brighton criteria level 1–3 for GBS were met. The IR was fairly stable over 30 years at 1.77 per 100,000 person years (95% CI: 1.70–1.84). The incidence was higher in the winter season (IR ratio compared with summer: 1.18 (95% CI: 1.09–1.29)), and was strongly associated with male gender (IR ratio vs females: 1.44 (95% CI: 1.33–1.57)). IRs rose with age at diagnosis, particularly after the age of 50 in both men and women and a minor peak was observed for total IR in young adults. Conclusion: Primary diagnostic codes for GBS at Danish departments of neurology have high validity. The DNPR is a well-suited data source for epidemiological research on GBS. The Danish nationwide 30-year GBS IR is stable over time and similar to GBS IRs reported in other European and North American populations. Dove 2019-04-18 /pmc/articles/PMC6497480/ /pubmed/31114387 http://dx.doi.org/10.2147/CLEP.S199839 Text en © 2019 Levison et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Levison, Lotte Sahin
Thomsen, Reimar Wernich
Christensen, Diana Hedevang
Mellemkjær, Thomas
Sindrup, Søren Hein
Andersen, Henning
Guillain-Barré syndrome in Denmark: validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period
title Guillain-Barré syndrome in Denmark: validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period
title_full Guillain-Barré syndrome in Denmark: validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period
title_fullStr Guillain-Barré syndrome in Denmark: validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period
title_full_unstemmed Guillain-Barré syndrome in Denmark: validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period
title_short Guillain-Barré syndrome in Denmark: validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period
title_sort guillain-barré syndrome in denmark: validation of diagnostic codes and a population-based nationwide study of the incidence in a 30-year period
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497480/
https://www.ncbi.nlm.nih.gov/pubmed/31114387
http://dx.doi.org/10.2147/CLEP.S199839
work_keys_str_mv AT levisonlottesahin guillainbarresyndromeindenmarkvalidationofdiagnosticcodesandapopulationbasednationwidestudyoftheincidenceina30yearperiod
AT thomsenreimarwernich guillainbarresyndromeindenmarkvalidationofdiagnosticcodesandapopulationbasednationwidestudyoftheincidenceina30yearperiod
AT christensendianahedevang guillainbarresyndromeindenmarkvalidationofdiagnosticcodesandapopulationbasednationwidestudyoftheincidenceina30yearperiod
AT mellemkjærthomas guillainbarresyndromeindenmarkvalidationofdiagnosticcodesandapopulationbasednationwidestudyoftheincidenceina30yearperiod
AT sindrupsørenhein guillainbarresyndromeindenmarkvalidationofdiagnosticcodesandapopulationbasednationwidestudyoftheincidenceina30yearperiod
AT andersenhenning guillainbarresyndromeindenmarkvalidationofdiagnosticcodesandapopulationbasednationwidestudyoftheincidenceina30yearperiod